Risk factor
Considerable default risk
Profitability factor
Greatly overvalued vs peers
About
Oscotec Inc. operates as a clinical stage drug discovery and development company. It develops SYK inhibitor that is in Phase IIa clinical trial to treat rheumatoid arthritis and immune thrombocytopenia; FLT3 inhibitor, which is in Phase I clinical trial for the treatment of acute myeloid leukemia; and EGFR double mutation inhibitor to treat non-small cell...
Company Valuation
Considering past and projected metrics, the stock is distinctly 'expensive' compared to its peers. Specifically, the stock is 'expensive' on P/E.
Target Price
The average target price of 039200.KQ is 58861 and suggests 13% upside potential. Usually, this means a HOLD recommendation among investment firms. This neutral recommend
Buy
Sell